Ibrutinib‐mediated relapse in CLL is mostly associated with genomic alterations in BTK and its downstream target PLCγ2, but cases of progressive disease in which targeted sequencing is unable to explain resistance have also been reported (Landau et al., 2017). This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.